6 completed, 1 unknown. 7 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 6, Unknown 1 |
| Phase 2 | 3 | Completed 2, Unknown 1 |
Follow mRNA-1273: new trials by email Literature Review of mRNA-1273 trials Research Report on mRNA-1273
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Modified mRNA Vaccines in Healthy Adults mRNA-1273, mRNA-1010, mRNA-1345 - SARS-CoV-2, Seasonal Influenza | Phase 1 | Completed | ModernaTX, Inc. | 308 | 2022-05-24 | 2026-03-12 |
| A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years Old mRNA-1073, mRNA-1010, mRNA-1273 - SARS-CoV-2, Influenza | Phase 1 / Phase 2 | Completed | ModernaTX, Inc. | 550 | 2022-05-13 | 2024-02-28 |
| The Immune Response of Heterologous Boost Third Dose of mRNA and Protein COVID-19 Vaccine BNT162b2, mRNA-1273, MVC-COV1901 - COVID-19, Breakthrough Infection | Phase 1 / Phase 2 | Unknown | Chang Gung Memorial Hospital | 340 | 2021-11-30 | 2022-07-25 |
| Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines Ad26.COV2.S, BNT162b2, mRNA-1273 - COVID-19 | Phase 1 / Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 867 | 2021-05-28 | 2025-04-20 |
| Safety and Immunogenicity Study of a SARS-CoV-2 (COVID-19) Variant Vaccine (mRNA-1273.351) in Naïve and Previously Vaccinated Adults mRNA-1273, mRNA-1273.351 - COVID-19, COVID-19 Immunisation | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 135 | 2021-03-31 | 2024-03-18 |
| A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19 mRNA-1283, mRNA-1273, Placebo - SARS-CoV-2 | Phase 1 | Completed | ModernaTX, Inc. | 104 | 2021-03-11 | 2023-08-01 |
| Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19) mRNA-1273 - COVID-19, COVID-19 Immunisation | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 120 | 2020-03-16 | 2024-03-18 |
COVID-19 (6) · Coronavirus Infections (3) · Influenza, Human (2) · Virus Diseases (2) · Breakthrough Infections (1) · Cytomegalovirus Infections (1)
ModernaTX, Inc. (3) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · Chang Gung Memorial Hospital (1)
United States (6) · Taiwan (1)
Cheng-Hsun Chiu, MD, PhD (1) · Kirsten E Lyke, M.D. (1) · Robert L Atmar, M.D. (1)
PMID 35547849, PMID 32663912, PMID 32991794, PMID 34090865, PMID 34642699, PMID 35072628, PMID 35081293, PMID 35126362, PMID 35798000, PMID 36399969, PMID 37074202, PMID 37433788, PMID 37992183, PMID 39481241, PMID 40276503, PMID 40298376, PMID 40632654, PMID 41398408, PMID 41535296, PMID 41627968
5UM1AI148373-05 (2), 5UM1AI148684-02 (1)